A pioneering public-private research initiative between GSK, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute is to harness the power of 'big data' and genome sequencing to improve the success rate for discovering new medicines.
The CTTV aims to use the almost daily advances in cutting-edge genetic research to help researchers in that crucial first step in exploring new medicines - finding where to start. Target validation is about clearly defining the role that a biological process plays in disease before developing a new drug to tackle it.
Currently, an estimated 90 per cent of compounds entering clinical trials fail to demonstrate the necessary efficacy and safety requirements, never reaching patients as medicines. This is often because the biological target for a drug is not well understood.
No comments:
Post a Comment